What do systematic reviews say?

Immunomodulatory drug maintenance therapy vs placebo/observation

Immunomodulatory drug maintenance therapy showed no clear difference in treatment‐related mortality compared with placebo/observation (low certainty).

• Maintenance therapy for chronic lymphocytic leukaemia 2024 · Cochrane Headline outcomes only
  Risk ratio 1.22 [0.35, 4.29]
  3 studies · 458 participants
  Low

Anti‐CD20 mAb maintenance therapy vs observation

Anti‐CD20 mAb maintenance therapy showed no clear difference in treatment‐related mortality compared with observation (low certainty).

• Maintenance therapy for chronic lymphocytic leukaemia 2024 · Cochrane Headline outcomes only
  Risk ratio 0.82 [0.39, 1.71]
  4 studies · 1189 participants
  Low

Nivolumab vs no other intervention

The review found no eligible studies for this question.

• Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• The role of iron in the management of chemotherapy‐induced anemia in cancer patients receiving… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 997 participants
  High

Intervention not reported

• Interleukin‐2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission 2015 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Intervention not reported

The review found no eligible studies for this question.

• The role of additional radiotherapy for primary central nervous system lymphoma 2014 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin

• First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors compared with first‐line… 2013 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 54 participants
  Very low

Intervention not reported

The intervention showed no clear difference in treatment‐related mortality (moderate certainty).

• High‐dose therapy with autologous stem cell transplantation versus chemotherapy or immuno‐chemotherapy for follicular… 2012 · Cochrane Headline outcomes only
  RR 1.28 [0.25, 6.61]
  4 studies · 941 participants
  Moderate

Cytarabine plus high‐dose methotrexate vs high‐dose methotrexate alone

Cytarabine plus high‐dose methotrexate showed no clear difference in treatment‐related mortality compared with high‐dose methotrexate alone (moderate certainty).

• Role of chemotherapy additional to high‐dose methotrexate for primary central nervous system lymphoma (PCNSL) 2012 · Cochrane Headline outcomes only
  RR 3.08 [0.33, 28.32]
  1 study · 79 participants
  Moderate

Anti‐CD52 mAb maintenance therapy vs observation

The review found no eligible studies for this question.

• Maintenance therapy for chronic lymphocytic leukaemia 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Escalated BEACOPP vs chemotherapy including ABVD

Escalated BEACOPP showed no clear difference in adverse event: treatment‐related mortality compared with chemotherapy including ABVD (low certainty).

• Comparison of first‐line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with… 2017 · Cochrane Headline outcomes only
  RR 2.15 [0.93, 4.95]
  4 studies · 2700 participants
  Low

Intervention not reported

The intervention showed no clear difference in treatment‐related mortality ‐ overall analysis (at 3 years) (moderate certainty).

• High‐dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin… 2013 · Cochrane Headline outcomes only
  RR 0.61 [0.16, 2.22]
  2 studies · 157 participants
  Moderate